KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma

References

• Parekh HD, Starr J, George TJ Jr. The multidisciplinary approach to localized pancreatic adenocarcinoma. Curr Treat Options Oncol. 2017;18(12):73. doi:10.1007/s11864-017-0515-8
   PubMed Web of Science ®Google Scholar
• McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861. doi:10.3748/wjg.v24.i43.4846
   PubMed Web of Science ®Google Scholar
• Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for recurrent pancreatic cancer: is it effective? Cancers (Basel). 2019;11:7. doi:10.3390/cancers11070991
   Web of Science ®Google Scholar
• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705. doi:10.3748/wjg.v22.i44.9694
   PubMed Web of Science ®Google Scholar
• Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma. Cancers (Basel). 2018;10:6. doi:10.3390/cancers10060193
   PubMed Web of Science ®Google Scholar
• Jacob JT, Coulombe PA, Kwan R, Omary MB, Types I, Keratin Intermediate II. Filaments. Cold Spring Harb Perspect Biol. 2018;10:4. doi:10.1101/cshperspect.a018275
   Web of Science ®Google Scholar
• Pan X, Hobbs RP, Coulombe PA. The expanding significance of keratin intermediate filaments in normal and diseased epithelia. Curr Opin Cell Biol. 2013;25(1):47–56. doi:10.1016/j.ceb.2012.10.018
   PubMed Web of Science ®Google Scholar
• Kryvenko ON, Jorda M, Argani P, Epstein JI. Diagnostic approach to eosinophilic renal neoplasms. Arch Pathol Lab Med. 2014;138(11):1531–1541. doi:10.5858/arpa.2013-0653-RA
   PubMed Web of Science ®Google Scholar
• Luo H-T, Liang C-X, Luo R-C, Gu W-G. Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Biosci Rep. 2017;37:6. doi:10.1042/BSR20171086
   Web of Science ®Google Scholar
• Liu L-Z, Yang L-X, Zheng B-H, et al. CK7/CK19 index: a potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. J Surg Oncol. 2018;117(7):1531–1539. doi:10.1002/jso.25027
   PubMed Web of Science ®Google Scholar
• Schüssler MH, Skoudy A, Ramaekers F, Real FX. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol. 1992;140(3):559–568.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi:10.5114/wo.2014.47136
   PubMedGoogle Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W1. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Pontén F, Schwenk JM, Asplund A, Edqvist PHD. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011;270(5):428–446. doi:10.1111/j.1365-2796.2011.02427.x
   PubMed Web of Science ®Google Scholar
• Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer. 2014;14:970. doi:10.1186/1471-2407-14-970
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Miao Y-R, Zhang Q, Lei Q, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weinh). 2020;7(7):1902880. doi:10.1002/advs.201902880
   PubMedGoogle Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261. doi:10.1093/nar/gkg034
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(WebServer issue):W169–W175. doi:10.1093/nar/gkm415
   PubMed Web of Science ®Google Scholar
• Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res. 2018;46(W1):W60–W64. doi:10.1093/nar/gky311
   PubMed Web of Science ®Google Scholar
• Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm369
   PubMed Web of Science ®Google Scholar
• Hashiguchi M, Masuda M, Kai K, et al. Decreased cytokeratin 7 expression correlates with the progression of cervical squamous cell carcinoma and poor patient outcomes. J Obstet Gynaecol Res. 2019;45(11):2228–2236. doi:10.1111/jog.14108
   PubMed Web of Science ®Google Scholar
• Shi R, Wang C, Fu N, et al. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer. Oncol Rep. 2019;41(5):3015–3026. doi:10.3892/or.2019.7069
   PubMed Web of Science ®Google Scholar
• Mehrpouya M, Pourhashem Z, Yardehnavi N, Oladnabi M. Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods. J Cell Physiol. 2019;234(12):21425–21435. doi:10.1002/jcp.28768
   PubMed Web of Science ®Google Scholar
• Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells. 2019;8:5. doi:10.3390/cells8050497
   Web of Science ®Google Scholar
• Hegde S, Krisnawan VE, Herzog BH, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37(3):289–307.e289. doi:10.1016/j.ccell.2020.02.008
   PubMed Web of Science ®Google Scholar
• Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 2016;6(4):400–413. doi:10.1158/2159-8290.CD-15-1032
   PubMed Web of Science ®Google Scholar
• Lee HS, Leem G, Kang H, et al. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2020.
   Web of Science ®Google Scholar
• Nizri E, Bar-David S, Aizic A, et al. Desmoplasia in lymph node metastasis of pancreatic adenocarcinoma reveals activation of cancer-associated fibroblasts pattern and T-helper 2 immune cell infiltration. Pancreas. 2019;48(3):367–373. doi:10.1097/MPA.0000000000001261
   PubMed Web of Science ®Google Scholar
• Janakiram NB, Mohammed A, Bryant T, et al. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. Immunology. 2017;152(1):36–51. doi:10.1111/imm.12746
   PubMed Web of Science ®Google Scholar
• Daley D, Zambirinis CP, Seifert L, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation. Cell. 2016;166:6. doi:10.1016/j.cell.2016.07.046
   Web of Science ®Google Scholar
• Wang Z, Zhao J, Zhao H, et al. Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer. Int J Clin Exp Pathol. 2017;10(8):8820–8828.
   PubMed Web of Science ®Google Scholar
• Salas PJ, Forteza R, Mashukova A. Multiple roles for keratin intermediate filaments in the regulation of epithelial barrier function and apico-basal polarity. Tissue Barriers. 2016;4(3):e1178368. doi:10.1080/21688370.2016.1178368
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Ozaki Y, Imazeki H, et al. Targeting Oncoimmune Drivers of Cancer Metastasis. Cancers (Basel). 2021;13:3. doi:10.3390/cancers13030554
   Web of Science ®Google Scholar
• Liu Q, Wu H, Li Y, et al. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunol Immunother. 2020;69(8):1477–1492. doi:10.1007/s00262-020-02542-7
   PubMed Web of Science ®Google Scholar
• Murter B, Pan X, Ophir E, et al. Mouse PVRIG has CD8 T cell-specific coinhibitory functions and dampens antitumor immunity. Cancer Immunol Res. 2019;7(2):244–256. doi:10.1158/2326-6066.CIR-18-0460
   PubMed Web of Science ®Google Scholar
• Stamm H, Klingler F, Grossjohann E-M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37(39):5269–5280. doi:10.1038/s41388-018-0288-y
   PubMed Web of Science ®Google Scholar
• Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121–144.
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35:2. doi:10.1016/j.ccell.2019.01.002
   Web of Science ®Google Scholar
• Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers (Basel). 2017;9:5. doi:10.3390/cancers9050042
   PubMed Web of Science ®Google Scholar
• Yuan R-H, Jeng Y-M, Hu R-H, et al. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 2011;15(2):321–329. doi:10.1007/s11605-010-1373-x
   PubMed Web of Science ®Google Scholar
• Cai B-H, Hsu P-C, Hsin IL, et al. p53 acts as a co-repressor to regulate keratin 14 expression during epidermal cell differentiation. PLoS One. 2012;7(7):e41742. doi:10.1371/journal.pone.0041742
   PubMed Web of Science ®Google Scholar